TGA / PMDA / NMPA · Asia-Pacific
efgartigimod alfa — TGA / PMDA / NMPA regulatory status
efgartigimod alfa (VYVGART) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: PMDA approved.
Status snapshot
- Status
- PMDA approved
- Brand
- VYVGART
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
- Target
- IgG receptor FcRn large subunit p51
- Structured fields
- 5
Pharmacology context used for competitive intelligence: IgG receptor FcRn large subunit p51 antagonist. Target: IgG receptor FcRn large subunit p51. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — PMDA: approved.
Linked evidence on this spoke: 0 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| PMDA | Japan | approved | — | Evidence |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of efgartigimod alfa?
efgartigimod alfa currently shows PMDA approved in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get efgartigimod alfa regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.